Evicenter
MarkdownMedical informationP&T meetings
Lanifibranor (IVA337)

Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

Manufacturer
Inventiva
Last updated
220 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis

Economic impact of Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis on families

1 evidence topic · 1 source

Informal and professional caregiver costs by fibrosis stage in adults with NASH, United States and five European countries, GAIN study
Mean annual direct non-medical cost per patient (SD), patient-reportedEarly fibrosis (n = 546)Advanced fibrosis (n = 221)USA (n = 97)
Non-medical“€1,704 (5,785)”View highlighted excerpt for this quote“€4,661 (9,839)”View highlighted excerpt for this quote“€3,243 (7,685)”View highlighted excerpt for this quote